Cell line · CVCL_0312
Papers55
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 55
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. | Sci Prog | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ANXA3 activates HIF-1α/VEGF Signaling Via the PI3K/AKT/mTOR Pathway to Promote Osteosarcoma Stem Cell-Like Phenotype. | Stem Cell Rev Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ldha Regulates Osteosarcoma Lung Metastasis through Hedgehog Signaling. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine Learning-Based Identification and Validation of PYCR1 and PYGM as Prognostic Biomarkers for Osteosarcoma. | Clin Med Insights Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2-COL3A1 axis. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Neutrophil elastase promotes low molecular weight cyclin E1 formation to accelerate osteosarcoma proliferation. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Methionine intervention induces PD-L1 expression to enhance the immune checkpoint therapy response in MTAP-deleted osteosarcoma. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. | Oncogene | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MTF2 facilitates the advancement of osteosarcoma through mediating EZH2/SFRP1/Wnt signaling. | J Orthop Surg Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Membrane HIV-1 envelope glycoproteins stabilized more strongly in a pretriggered conformation than natural virus Envs. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases. | Discov Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Circ_0002669 promotes osteosarcoma tumorigenesis through directly binding to MYCBP and sponging miR-889-3p. | Biol Direct | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification of TNFRSF21 as an inhibitory factor of osteosarcoma based on a necroptosis-related prognostic gene signature and molecular experiments. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| CCDC85A is regulated by miR-224-3p and augments cancer cell resistance to endoplasmic reticulum stress. | Front Oncol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A general method for quantitative fractionation of mammalian cells. | J Cell Biol | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0312/papers